Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 1, 2003, Pages 1-16

  Hinderling, Peter H ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Absolute bioavailability; Bias; Oral data; Renal function

Indexed keywords

ACEBUTOLOL; AMPICILLIN; ATENOLOL; AZTREONAM; BISOPROLOL; CARTEOLOL; CARUMONAM; CEFMENOXIME; CEFONICID; CEFOTIAM; CEFSULODIN; CEFTAZIDIME; CIDOFOVIR; CIPROFLOXACIN; ENOXACIN; FAMOTIDINE; FLECAINIDE; FLEROXACIN; GABAPENTIN; GANCICLOVIR; MEROPENEM; METOCLOPRAMIDE; PIPERACILLIN; RANITIDINE; RISEDRONIC ACID; ROXATIDINE; SEMATILIDE; SOTALOL; SULBACTAM; UNINDEXED DRUG;

ACCURACY; ANALYTICAL ERROR; AREA UNDER THE CURVE; CONTROLLED STUDY; DATA ANALYSIS; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; KIDNEY CLEARANCE; KIDNEY FUNCTION; RELIABILITY; REVIEW; STATISTICAL PARAMETERS;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; DATABASES, FACTUAL; HUMANS; LINEAR MODELS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; STATISTICS;

EID: 0037243849     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.320     Document Type: Review

References (128)

1. Hinderling PH, Shi J. Absolute bioavailability estimates from oral data. J Pharm Sci 1995; 84: 385-386.
2. Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker. Inc:. New York, 1975; 147-153.
3. Mahmood I. Prediction of absolute bioavailability for drugs using oral, renal clearance following a single oral dose: A critical view. Biopharm Drug Dispos 1997; 18: 465-473.
4. Hinderling P. Commentary Prediction of absolute bioavailability for drugs using oral, renal clearance following a single oral dose: A critical review. Biopharm Drug Dispos 1997; 18: 821-824.
5. Hinderling PH. Biased estimates of nonrenal clearance. J Pharm Sci 2000; 90: 960-966.
6. Senello LT, Finlay RA, Chu S, et al. The effect of impaired renal function on the multiple dose clinical pharmacokinetics of carteolol. Adv Therapy 1987; 4: 298-308.
7. Lameire N, Rosenkranz B, Maass L, Brockmeier D. A pharmacokinetic study of roxatidine in chronic renal failure. Drugs 1988; 35 (Suppl. 3): 48-52.
8. Mitchell DY, Barr WH, Eusebio RA, et al. Determination of intravenous pharmacokinetics, absolute and relative bioavailability, and intra- and intersubject variability of risedronate using a four period replicate study design. Pharm Res 1997; 14: 5610.
9. Lam YWF, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997; 32: 330-57.
10. SYSTAT version 7.0, SPSS: Chicago IL, 1997; 60611-3962.
11. Gambertoglio JG, Alexander DP, Barriere SL. Cefmenoxim pharmacokinetics in healthy volunteeers and subjects with renal insufficiency and on hemodialysis. Antimicrob Agents Chemother 1984; 26: 845-849.
12. Polk RE, Sica DA, Kerkering TM, Kline BJ, Patterson PM, Baggett JW. Antimicrob Agents Chemother 1984; 26: 322-327.
13. Barriere SL, Gambertoglio JG, Alexander DP. Stagg RJ, Conte JE. Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis. Rev Inf Dis 1984; 6 (Suppl. 4): S809-S815.
14. Van Dalen R, Vree TB, Baars AM, Termond E. Dosage adjustment for ceftazidime in patients with impaired renal function. Eur J Clin Pharmacol 1986; 30: 597-605.
15. Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P. Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high flux hemodialysis. Clin Pharmacol Ther 1999; 65: 21-28.
16. Shi J, Ripley E, Gehr TWB, Sica DA, Dandekar KA, Hinderling PH. Pharmacokinetics of sematilide in renal failure. J Clin Pharmacol 1996; 36: 131-143.
17. Ishizaki T, Ohnishi A. Sasaki T, et al. Pharmacokinetics and absolute bioavailability of carteolol, a new β-adrenergic receptor blocking agent. Eur Clin Pharmacol 1983; 25: 95-101.
18. Hasenfuss G, Schaefer-Korting, Knauf H, Mutschler E, Just H. Pharmacokinetics of carteolol in relation to renal function. Eur J Clin Pharmacol 1985; 29: 461-465.
19. Dumas M, D'Athis P, Besancenot JF, et al. Variations of sotalol kinetics in renal insufficiency. J Clin Pharm Ther Tox 1989; 27: 486-463.
20. Berlex Laboratories Inc., Report 98186, 1998.
21. Anttila M, Arstila, Pfeffer M, Tikkanen R, Valinkoski V, Sundquvist H. Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol 1976; 39: 118-128.
22. Poirier JM, Aubry JP, Cheymol G, Jaillon P. Etude pharmacocinetique du sotalol administre par voie intraveneuse chez l'homme sain. Therapie 1981; 36: 4.
23. Poirier JM, Jaillon P, Lecocq B, Lecocq V, Ferry A, Cheymol G. The pharmacokinetics of d- sotalol and d/l sotalol in healthy volunteers. Eur J Clin Pharmacol 1990; 38: 579-582.
24. Sedman AJ, personal communication, 1997.
25. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994; 56: 154-159.
26. Schmidt B. Potential antiepileptic drugs; gabapentin. In: Antiepileptic drugs (3rd edn.), Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE. (eds). Raven Press: New York, 1989; 925-935.
27. McAinsh J, Holmes BF, Smith S, Hood D, Warren D. Atenolol kinetics in renal failure. Clin Pharmacol Ther 1980; 28: 302-309.
28. Mason W, Winer N, Kochak G, Cohen I, Bell R. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther 1979; 25: 408-415.
29. Kirch W, Koehler H, Mutschler, Schaefer M. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol 1981; 19: 65-71.
30. Kirch W, Rose I, Demers HG, Leopold G, Pabst J, Ohnhaus EE. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet 1987; 13: 110-117.
31. Leopold G, Pabst J, Ungethuem W, Buehring KU. Basic pharmacokinetics of bisoprolol, a highly beta1-selective adrenoceptor antagonist. J Clin Pharmacol 1986; 26: 616-621.
32. Singlas E, Leroy A, Sultan E, et al. Disposition of fleroxacin, a new trifluroquinolone, and its metabolites: Pharmacokinetics in renal failure and influence of hemodialysis. Clin Pharmacokinet 1990; 19: 67-79.
33. Tabouret AM. Personal communication, 1996.
34. Stuck AE, Frey F, Heizmann P, Brandt R, Weidekamm E. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1989; 33: 373-381.
35. Mitchell DY, St.Peter JV, Eusebio RA, et al. Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 2000; 49: 215-222.
36. Bender W, Brockmeier D. Pharmacokinetic characteristics of roxatidine. J Clin Gastroenterol 1989; 11(Suppl.1): S6-S19.
37. Taylor EA, Turner P. The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma. Br J Clin Pharmacol 1981; 12: 543-548.
38. Rouan MC, Binswanger U, Bamatter F, Theobald W, Schoeller JP, Guibert J. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients. J Antimicrob Chemother 1984; 13: 611-618.
39. Matzke G, Keane WF. Cefsulodin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1983; 23: 369-373.
40. Gibson TP, Granneman R, Kallal JE, Senello LT. Cefsulodin kinetics in renal impairment. Clin Pharmacol Ther 1982; 31: 602-608.
41. Lehmann CR, Heironimus JD, Collins CB, et al. Metoclopramide kinetics in patients with impaired renal function and clearance by hemodialysis. Clin Pharmacol Ther 1985; 37: 284-289.
42. Bury RW, Becker GJ, Kincaid-Smith PS, Moulds RFW, Witworth JA. Elimination of enoxacin in renal disease. Clin Pharmacol Ther 1987; 41: 434-438.
43. Chang T, Black A, Dunky A, et al. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. J Antimicrob Chemother 1988; 21 (Suppl B): 49-56.
44. Roux A, Aubert P, Guedon P, Flouvat B. Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol 1980; 17: 339-348.
45. Meffin PJ, Winkle RA, Peters FA, Harrison DC. Acebutolol disposition after intravenous administration. Clin Pharmacol Ther 1977; 22: 557-567.
46. Meffin PJ, Winkle RA, Peters FA, Harrison DC. Dose dependent acebutolol disposition after oral administration. Clin Pharmacol Ther 1978; 24: 542-547.
47. Braun J, Kollert JR, Becker JU. Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal function. Eur J Clin Pharmacol 1987; 31: 711-714.
48. Conard GJ, Carlson GL, Frost JW, Ober RE. Human plasma pharmacokinetics of flecainide acetate (R-818), a new antiarrhythmic, following single oral and intravenous doses. Clin Pharmacol Ther 1979; 25: 218.
49. Hage K, Buehl K, Fischer C, Knebel NG. Estimation of absolute bioavailability of flecainide using stable isotope technique. Eur J Clin Pharmacol 1995; 48: 51-55.
50. Tjandra-Maga TB, Verbesselt R, van Hecken A, Mullie A, de Schepper PJ. Flecainide: Single and multiple oral dose kinetics, absolule bioavailability and effect of food and antacid in man. Br J Clin Pharmacol 1986; 22: 309-316.
51. Hinderling PH, Schmidlin O, Seydel JK. Structure-pharmacokinetic relationships of β-adrenoceptor antagonists in humans. J Pharmacokin Biopharm 1984; 11: 263-287; 659-666.
52. Mikus G, Gross AS, Beckmannn J, Hertrampf R, Gundert-Remy U, Eichelbaum M. The influence of the spartein/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 1989; 45: 562-567.
53. Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M. Stereoselective disposition of flecainide in relation to the spartein/debrisoquin metaboliser phenotype. Br J Clin Pharmacol 1989; 28: 5555-566.
54. Johnstone A, Warrington S, Turner P. Flecainide pharmacokinetics in healthy volunteers: The influence of urinary pH. Br J Clin Pharmacol 1985; 20: 333-381.
55. Horber F, Egger HJ, Weidekamm E, et al. Pharmacokinetics of carumonam in patients with renal insufficiency. Antimicrob Agents Chemother 1986; 29: 116-121.
56. Christensson BA, Nilsson-Ehle I, Hutchinson M, Haworth SJ, Oeqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 1993; 36: 1532-1537.
57. Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 1992; 36: 2794-2798.
58. Mihindu JCL, Scheld M, Bolton ND, Spyker DA, Bolton WK. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Ag Chemother 1983; 24: 252-261.
59. Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother 1984; 25: 201-204.
60. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DP, Pittman KA. Pharmacokinetics of cefepim in subjects with renal insufficiensy. Clin Pharmacol Ther 1990; 24: 268-276.
61. Halstenson CE, Guay DRP, Opsahl JA, et al. Disposition of cefmetazole in healthy volunteers and patients with imapired renal function. Antimicrob Agents Chemother 1990; 34: 519-523.
62. Kneer J, Tam YK, Blouin RA, et al. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency. Antimicrob Agents Chemother 1989; 33: 1952-1957.
63. Blair AD, Maxwell BM, Forland S, Jacob L, Cutler RE. Cefonicid kinetics in subjects with normal and impaired renal function. Clin Pharmacol Ther 1983; 35: 798-803.
64. Phelps RT, Conte JE. Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function. Antimicrob Agents Chemother 1986; 29: 913-917.
65. Somadossi JP, Bevan R, Ling T, et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Reviews Infect Dis 1988; 10 (Suppl 3): S507-S514.
66. Reitberg DP, Marble DA, Schultz RW, Whall TJ, Schentag JJ. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1988; 32: 503-509.
67. Blum RA, Kohli RK, Harrison NJ, Schentag JJ. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1989; 33: 1470-1476.
68. Fillastre JP, Leroy A, Baudoin C, et al. Pharmacokinetics of aztreonam in patients with chronic failure. Clin Pharmacokinet 1985; 10: 91-100.
69. Takabatake T, Ohta H, Yamamoto Y, et al. Pharmacokinetics of TZU-0460, a new H2-receptor antagonist, in patients with impaired renal function. Eur J Clin Pharmaccol 1986; 30: 709-712.
70. Halstenson CE, Abraham PA, Opsahl JA, Chremos AN, Keane WF, Matzke GR. Disposition of famotidine in renal insufficiency. J Clin Pharmacol 1987; 27: 782-787.
71. Lin JH, Chremos AN, Yeh KC, Antonello J, Hessey II GA. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol 1988; 34: 41-46.
72. Shah A, Lettieri J, Blum R, Millikin S, Sica D, Heller AH. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. J Antimicrob Ther 1996; 38: 103-116.
73. Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother 1987; 31: 860-864.
74. Canal M, Flouvat B, Tremblay D, Dufour A. Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline. Eur J Clin Pharmacol 1983; 24: 509-515.
75. Canal M, Flouvat B, Aubert P, Guedon J, Prinseau J, Baglin A. Pharmacokinetics of cibenzoline in patients with renal impairment. J Clin Pharmacol 1985; 25: 197-203.
76. Bundtzen RW, Toothaker RD, Nielson OS, Madsen PO, Welling PG, Craig WA. Pharmacokinetics of cefuroxim in normal and impaired renal function: Comparison of high-pressure liquid chromatography and microbiological assays. Antimicrob Agents Chemother 1981; 19: 443-449.
77. Meffin PJ, Grgurinovich N, Broooks PM, Miners OJ, Cochran M, Stranks G. Ranitidine disposition in patients with renal impairment. Br J Clin Pharmacol 1983; 16: 731-734.
78. Johnson CA, Halstenson CE, Kelloway JS. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 1992; 51: 32-41.
79. Shen DD, Cunningham JL, Shudo I, Azarnoff DL. Disposition kinetics of disopyramide in patients with renal insufficiency. Biopharm Drug Disp 1980; 1: 133-140.
80. Burk M, Peters U. Disopyramide kinetics in renal impairment:Determinants of individual variability. Clin Pharmacol Ther 1983; 34: 331-340.
81. Molander L, Hansson A, Lunell E, Alainentalo L, Hoffmann M, Larsson R. Pharmacokinetics of nicotine in kidney failure. Clin Pharmacol Ther 2000; 68: 250-260.
82. Smith BR, LeFrock JL, Thyrum PT, et al. Cefotetan pharmacokinetics in volunteers with various degrees of renal function. Antimicrob Agents Chemother 1986; 29: 887-893.
83. Matzke GR, Abraham PA, Halstensson CE, Keane WF. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther 1985; 38: 31-36.
84. Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired function. Reviews Infect Dis 1982; 4 (Suppl): S379-S391.
85. Duloisio JT. Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function. Reviews Infect Dis 1982; 4(Suppl): S333-S345.
86. Saha H, Castren-Kortekangas P, Ojanen S, et al. Pharmacokinetics of clodronate in renal failure. J Bone Mineral Res 1994; 9: 1953-1958.
87. O'Rourke NPO, McCloskey EV, Neugebauer G, Kanis JA. Renal and nonrenal clearance in patients with malignancy and renal impairment. Drug Invest 1994; 7: 26-33.
88. Krakamp B, Tanswell P, Vogel H, Bozler G. Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction. Eur J Clin Pharmacol 1989; 36: 75-78.
89. Conte JE, Jr. Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function. Antimicrob Agents Chemother 1987; 31: 1585-1588.
90. Nix DE, Schultz RW, Frost RW, et al. The effect of renal impairment and hemodialysis on single dose pharmacokinetics of oral enoxacin. J Antimicrob Chemother 1988; 21(Suppl B): 87-95.
91. Aronoff GR, Bergstroem RF, Bopp RJ, Sloan RS, Callaghan JT. Nizatidine disposition in subjects with normal and impaired renal function. Clin Pharmacol Ther 1988; 43: 688-695.
92. Blum RA, Schultz RW, Schentag JJ. Pharmacokinetics of lomefloxacin in renally compromised patients. Antimicrob Agents Chemother 1990; 34: 2364-2368.
93. Bogg EJ, Robson RA, Bailey RR, Lynn KL, Frank GJ, Olson SC. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment. Br J Clin Pharmacol 1990; 30: 213-220.
94. Flor S, Guay D, Opsahl J, Tack K, Matzke G. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment. Int J Clin Pharm Res 1992; 11: 115-121.
95. Blair AD, Burgess ED, Maxwell BM, Cutler RE. Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 1981; 29: 457-463.
96. St.Peter JV, Borin MT, Hughes GS, Kelloway, Shapiro BE, Halstenson CE. Disposition of cefpodoxim proxetil in healthy volunteers and patients with impaired renal function. Antimicrob Agents Chemother 1992; 36: 126-131.
97. Dhib M, Moulin B, Leroy A, et al. Relationship between renal function and disposition of oral cefixime. Eur J Clin Pharmacol 1991; 41: 579-583.
98. Therasse DG, Farlo DS, Davidson RL, et al. Effects of renal dysfunction on the pharmacokinetics of loracarbef. Clin Pharmacol Ther 1993; 54: 311-316.
99. Sambol N, Chiang J, Lin ET, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995; 35: 1094-1102.
100. Pentikaeinen PJ, Neuvonen PJ, Penttilae A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16: 195-202.
101. Boyke SC, Pue MA, Freed MI, et al. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment. Clin Pharmacol Ther 1994; 55: 418-426.
102. Fowles SE, Pierce DM, Prince WT, Staniforth D. The tolerance to and pharmacokinetics of penciclovir (BRL 39123A), a novel antiherpes agent, administered by intravenous infusion to healthy subjects. Eur J Clin Pharmacol 1992; 43: 513-516.
103. Weidekamm E, Portmann I, Suter K, Partos C, Dell D, Luecker PW. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrob Agents Chemother 1987; 31: 1909-1914.
104. Halstenson, Opsahl JA, Abraham PA, et al. Disposition of guanadrel in subjects with normal and impaired renal function. J Clin Pharmacol 1989; 29: 128-132.
105. Halstenson CE, Opsahl JA, Wright E, et al. Disposition of minoxidil in patients with various degrees of renal function. J Clin Pharmacol 1989; 29: 798-802.
106. Skoutakis VA, Acchiardo SA, Carter CA, et al. Pharmacokinetics of cetamolol in hypertensive patients with normal and compromised renal function. J Clin Pharmacol 1988; 28: 467-476.
107. Fillastre JP, Moulin B, Godin M, et al. Pharmacokinetics of cilazapril in patients with renal failure. Br J Clin Pharmacol 1989; 27: 275S-282S.
108. Whitehead EM, Walters GE, Williams PEO, Johnston GD. Pharmacokinetics of intravenous cilazaprilat in normal volunteers. Br J Clin Pharmacol 1989; 27: 873-875.
109. Forrest A, Weir M, Plaisance KI, Drusano GL, Leslie J, Standiford HC. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrob Agents Chemother 1988; 32: 1537-1540.
110. Forland SC, Cutler RE, McQuinn RL, et al. Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. J Clin Pharmacol 1988; 28: 727-735.
111. Guay DRP, Meatherall RC, Harding GK, Brown GR. Pharmacokinetics of cefixime (CL 284, 635; FK 027) in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother 1986; 30: 485-490.
112. Foote EF, Lee DR, Karim A, Keane WF, Halstenson CE. Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function. J Clin Pharmacol 1995; 35: 384-389.
113. Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994; 56: 1421.
114. Chandler MH, Schran HF, Cutler RE, Smith AJ, Gonasun LM, Blouin RA. The effects of renal function on the disposition of isradipine. J Clin Pharmacol 1988; 28: 1076-1080.
115. St.Peter JV, Lambrecht LJ, Gunderson BW, Andersen SA, Gallagher SC, Swan SK. Pharmacokinetics of pilocarpin in subjects with varying degrees of renal function. J Clin Pharmacol 2000; 40: 1470-1475.
116. Aromdee C, Ferguson MM, Ledger R, Wall J. A pilot study of the disposition of pilocarpin in plasma, saliva and urine after a single oral dose. Eur J Pharm Sci 1999; 8: 81-83.
117. Dettli L. Individualization of drug dosage in patients with impaired renal function. Med Clin North Am 1974; 58: 977-985.
118. Reidenberg MM. The biotransformation of drugs in renal failure. Am J Med 1977; 62: 482-485.
119. Gibson TR. Renal disease and drug metabolism: An overview. Am J Kidney Dis 1986; 8: 7-17.
120. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. The Ann Pharmacother 1991; 25:1214-1223.
121. Hoeffler D, Koeppe P. Nonrenal clearance and tubular load in renal failure. Drug Res 1993; 43: 1233-1238.
122. Craig RM, Murphy P, Gibson TP, et al. Kinetic analysis of D-xylose absorption in normal subjects and in patients with chronic renal failure. J Lab Clin Med 1983; 101: 496-506.
123. Lunell E, Borga O, Larsson R. Pharmacokinetics of enprophylline in patients with impaired renal function after a single intravenous dose. Eur J Clin Pharmacol 1984; 26: 87-93.
124. Knupp CA, Hak LJ, Coakley DF, et al. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: Influence of hemodialysis and continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1996; 60: 535-542.
125. Ahmed JH, Grant AC, Rodger RSC, Murray GR, Elliott HL. Inhibitory effect of uremia on the hepatic clearance and metabolism of nicardipine. Br J Clin Pharmacol 1991; 32: 57-62.
126. Gibson TP, Atkinson AJ, Matusik E, Nelson LD, Briggs WA. Kinetics of procainamide and N-acetylprocainamide in renal failure. Kidney Int 1977; 12: 422-429.
127. Dreisbach AW, Japa S, Kamath BL, Gebrekal A, Tenaglia AN, Lertora JJL. Endstage renal disease (ESRD) reduces hepatic cytochrome P450 CYP2C9 activity. Clin Res 2002; 50: 157A
128. Mahmood I. Response to the comments on the commentary prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: A critical view. Biopharm Drug Dispos 1998; 19: 483-484.